Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Trinity Biotech plc

The latest announcement is out from Trinity Biotech ( ($TRIB) ). On November 18, 2025, Trinity Biotech announced it received World Health Organizat...

Trinity Biotech Secures WHO Approval for Offshore Manufacturing of HIV Test

The latest announcement is out from Trinity Biotech ( ($TRIB) ). On November 14, 2025, Trinity Biotech announced a strategic collaboration with a l...

Current Quarter	$-1.48	Next Quarter	$-1.28
Current Year	$-7.08	Next Year	$-4.36
QoQ Growth	+13.5%	YoY Growth	+38.4%
3Y EPS CAGR	+0.0%	Target Price	$15.00
Consensus	Buy	Upside	+1301.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TRIB	$1.07	0.00%	121.47K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TRIB	$1.07	0%	121.47K
3
4
5
6

TRIB

TRIB

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Trinity Biotech plc Data in Excel

Get Trinity Biotech plc Data in Excel